The Claim
In adults with type 2 diabetes and chronic kidney disease who are already receiving ACE inhibitor or ARB therapy, weekly subcutaneous administration of semaglutide at a dose of 1.0 mg reduces the risk of a composite outcome consisting of kidney failure, sustained estimated glomerular filtration rate (eGFR) decline of at least 50%, or death from kidney or cardiovascular causes by 24% compared to placebo over a median follow-up period of 3.4 years, with a number needed to treat of 20 to prevent one such event.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with type 2 diabetes and kidney problems, taking a weekly semaglutide shot (1.0 mg) can lower their chances of serious kidney or heart issues by about a quarter over 3.4 years — about 1 in every 20 people who take it will avoid a major problem.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease who are on ACE inhibitor or ARB therapy, weekly subcutaneous semaglutide at a dose of 1.0 mg reduces the risk of a composite outcome of kidney failure, sustained eGFR decline ≥50%, or death from kidney or cardiovascular causes by 24% compared to placebo over a median of 3.4 years, with a number needed to treat of 20 to prevent one event.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The study tested the exact same drug, dose, and patient group as described in the claim, and found it reduced serious kidney and heart problems by 24%, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.